JPH04505003A - 生体内の神経栄養、細胞保護性アルコール - Google Patents

生体内の神経栄養、細胞保護性アルコール

Info

Publication number: JPH04505003A
Authority: JP; Japan
Prior art keywords: neurons; damage; alcohol; injury; hexacosanol
Prior art date: 1988-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP1511596A

Other languages

English (en)

Japanese (ja)

Inventor

ボグ、ジャク

コトマン、カール　ダブリュ

ケスラック、ジェイ　パトリック

Original Assignee

ザレジェンツオブザユニバーシティオブカリフォルニア

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-18

Filing date

1989-10-16

Publication date

1992-09-03

1989-10-16 Application filed by ザレジェンツオブザユニバーシティオブカリフォルニア filed Critical ザレジェンツオブザユニバーシティオブカリフォルニア

1992-09-03 Publication of JPH04505003A publication Critical patent/JPH04505003A/ja

Status Pending legal-status Critical Current

Links

LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims description 46
230000000508 neurotrophic effect Effects 0.000 title claims description 13
238000001727 in vivo Methods 0.000 title description 23
230000001120 cytoprotective effect Effects 0.000 title description 2
IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 claims description 134
210000002569 neuron Anatomy 0.000 claims description 120
230000006378 damage Effects 0.000 claims description 110
238000000034 method Methods 0.000 claims description 104
208000014674 injury Diseases 0.000 claims description 59
208000027418 Wounds and injury Diseases 0.000 claims description 50
150000002191 fatty alcohols Chemical class 0.000 claims description 47
239000000203 mixture Substances 0.000 claims description 45
238000011084 recovery Methods 0.000 claims description 38
150000001875 compounds Chemical class 0.000 claims description 30
230000004083 survival effect Effects 0.000 claims description 30
238000011282 treatment Methods 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
230000003542 behavioural effect Effects 0.000 claims description 27
201000010099 disease Diseases 0.000 claims description 26
108010025020 Nerve Growth Factor Proteins 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 21
125000004432 carbon atom Chemical group C* 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 20
150000002148 esters Chemical class 0.000 claims description 19
238000001356 surgical procedure Methods 0.000 claims description 19
229940002612 prodrug Drugs 0.000 claims description 16
239000000651 prodrug Substances 0.000 claims description 16
239000005557 antagonist Substances 0.000 claims description 12
230000001737 promoting effect Effects 0.000 claims description 12
102000015336 Nerve Growth Factor Human genes 0.000 claims description 11
102000007072 Nerve Growth Factors Human genes 0.000 claims description 11
210000003169 central nervous system Anatomy 0.000 claims description 11
229940053128 nerve growth factor Drugs 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 10
239000000463 material Substances 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
230000034994 death Effects 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
239000004060 excitotoxin Substances 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 8
239000003257 excitatory amino acid Substances 0.000 claims description 8
230000002461 excitatory amino acid Effects 0.000 claims description 8
230000000926 neurological effect Effects 0.000 claims description 8
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 7
206010015037 epilepsy Diseases 0.000 claims description 7
210000001428 peripheral nervous system Anatomy 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000012549 training Methods 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
230000000324 neuroprotective effect Effects 0.000 claims description 6
239000000556 agonist Substances 0.000 claims description 5
239000000284 extract Substances 0.000 claims description 5
238000007918 intramuscular administration Methods 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
102000005962 receptors Human genes 0.000 claims description 5
108020003175 receptors Proteins 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
230000008717 functional decline Effects 0.000 claims description 4
239000003102 growth factor Substances 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
238000007914 intraventricular administration Methods 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
238000007912 intraperitoneal administration Methods 0.000 claims description 3
230000006386 memory function Effects 0.000 claims description 3
230000004693 neuron damage Effects 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
239000000018 receptor agonist Substances 0.000 claims description 3
229940044601 receptor agonist Drugs 0.000 claims description 3
206010008748 Chorea Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
102000018899 Glutamate Receptors Human genes 0.000 claims description 2
108010027915 Glutamate Receptors Proteins 0.000 claims description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
102000000079 Kainic Acid Receptors Human genes 0.000 claims description 2
108010069902 Kainic Acid Receptors Proteins 0.000 claims description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 2
102000013275 Somatomedins Human genes 0.000 claims description 2
230000002411 adverse Effects 0.000 claims description 2
206010008129 cerebral palsy Diseases 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims description 2
208000012601 choreatic disease Diseases 0.000 claims description 2
238000011260 co-administration Methods 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
210000002826 placenta Anatomy 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
230000000472 traumatic effect Effects 0.000 claims description 2
230000000626 neurodegenerative effect Effects 0.000 claims 2
229920002994 synthetic fiber Polymers 0.000 claims 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
229960001685 tacrine Drugs 0.000 claims 2
229940127291 Calcium channel antagonist Drugs 0.000 claims 1
239000000480 calcium channel blocker Substances 0.000 claims 1
230000003176 fibrotic effect Effects 0.000 claims 1
239000004090 neuroprotective agent Substances 0.000 claims 1
239000002581 neurotoxin Substances 0.000 claims 1
241000700159 Rattus Species 0.000 description 52
210000004556 brain Anatomy 0.000 description 52
241001465754 Metazoa Species 0.000 description 46
210000005036 nerve Anatomy 0.000 description 36
239000007924 injection Substances 0.000 description 24
238000002347 injection Methods 0.000 description 24
235000019441 ethanol Nutrition 0.000 description 23
238000012360 testing method Methods 0.000 description 23
210000004027 cell Anatomy 0.000 description 22
210000003050 axon Anatomy 0.000 description 20
230000008569 process Effects 0.000 description 19
230000006870 function Effects 0.000 description 17
230000001537 neural effect Effects 0.000 description 17
210000001519 tissue Anatomy 0.000 description 15
230000003492 excitotoxic effect Effects 0.000 description 14
230000008929 regeneration Effects 0.000 description 14
238000011069 regeneration method Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
230000013016 learning Effects 0.000 description 12
230000003902 lesion Effects 0.000 description 12
210000000278 spinal cord Anatomy 0.000 description 12
230000007850 degeneration Effects 0.000 description 11
231100000318 excitotoxic Toxicity 0.000 description 11
230000004770 neurodegeneration Effects 0.000 description 11
230000008733 trauma Effects 0.000 description 11
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
230000003376 axonal effect Effects 0.000 description 10
229930195712 glutamate Natural products 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
230000015654 memory Effects 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
230000012010 growth Effects 0.000 description 9
208000029028 brain injury Diseases 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
208000028867 ischemia Diseases 0.000 description 8
239000003900 neurotrophic factor Substances 0.000 description 8
230000001696 purinergic effect Effects 0.000 description 8
-1 amino acid glutamate Chemical class 0.000 description 7
230000006399 behavior Effects 0.000 description 7
210000002932 cholinergic neuron Anatomy 0.000 description 7
230000002354 daily effect Effects 0.000 description 7
229940105631 nembutal Drugs 0.000 description 7
208000015122 neurodegenerative disease Diseases 0.000 description 7
210000004498 neuroglial cell Anatomy 0.000 description 7
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
210000004761 scalp Anatomy 0.000 description 7
239000000758 substrate Substances 0.000 description 7
241000196324 Embryophyta Species 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000010171 animal model Methods 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
230000007423 decrease Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
210000001353 entorhinal cortex Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000000835 fiber Substances 0.000 description 6
229940126864 fibroblast growth factor Drugs 0.000 description 6
230000000971 hippocampal effect Effects 0.000 description 6
230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 6
239000002858 neurotransmitter agent Substances 0.000 description 6
210000000578 peripheral nerve Anatomy 0.000 description 6
238000011160 research Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
208000028389 Nerve injury Diseases 0.000 description 5
230000009471 action Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
230000006735 deficit Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
239000010931 gold Substances 0.000 description 5
229910052737 gold Inorganic materials 0.000 description 5
230000006872 improvement Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000008764 nerve damage Effects 0.000 description 5
210000000276 neural tube Anatomy 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
210000003625 skull Anatomy 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
208000013016 Hypoglycemia Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000560 biocompatible material Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
230000001605 fetal effect Effects 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
210000001320 hippocampus Anatomy 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
239000007943 implant Substances 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
230000016273 neuron death Effects 0.000 description 4
210000002475 olfactory pathway Anatomy 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000037361 pathway Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000001568 sexual effect Effects 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010001497 Agitation Diseases 0.000 description 3
208000034656 Contusions Diseases 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
238000009227 behaviour therapy Methods 0.000 description 3
230000002146 bilateral effect Effects 0.000 description 3
210000005056 cell body Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
230000003412 degenerative effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000003792 electrolyte Substances 0.000 description 3
231100000063 excitotoxicity Toxicity 0.000 description 3
239000003925 fat Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
210000003128 head Anatomy 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
210000002241 neurite Anatomy 0.000 description 3
230000002887 neurotoxic effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000008439 repair process Effects 0.000 description 3
208000020431 spinal cord injury Diseases 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000003826 tablet Substances 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
235000001270 Allium sibiricum Nutrition 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000007590 Calpain Human genes 0.000 description 2
108010032088 Calpain Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010052804 Drug tolerance Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
229930195714 L-glutamate Natural products 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
102000000471 Prostaglandin F receptors Human genes 0.000 description 2
108050008995 Prostaglandin F receptors Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000032683 aging Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
239000003194 amino acid receptor blocking agent Substances 0.000 description 2
238000002266 amputation Methods 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
210000001130 astrocyte Anatomy 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000007844 axonal damage Effects 0.000 description 2
210000003323 beak Anatomy 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000006727 cell loss Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000009519 contusion Effects 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 2
230000000254 damaging effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
210000003754 fetus Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
150000002306 glutamic acid derivatives Chemical class 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000026781 habituation Effects 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
102000048260 kappa Opioid Receptors Human genes 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000007659 motor function Effects 0.000 description 2
210000000944 nerve tissue Anatomy 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000014511 neuron projection development Effects 0.000 description 2
230000003955 neuronal function Effects 0.000 description 2
230000003961 neuronal insult Effects 0.000 description 2
230000006576 neuronal survival Effects 0.000 description 2
231100000189 neurotoxic Toxicity 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000000419 plant extract Substances 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000033458 reproduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000003497 sciatic nerve Anatomy 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
108020001588 κ-opioid receptors Proteins 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000030016 Avascular necrosis Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000002381 Brain Hypoxia Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
208000018380 Chemical injury Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
IOIMDJXKIMCMIG-UHFFFAOYSA-N Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)- Chemical compound CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C IOIMDJXKIMCMIG-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
206010053487 Exposure to toxic agent Diseases 0.000 description 1
238000001134 F-test Methods 0.000 description 1
206010018341 Gliosis Diseases 0.000 description 1
102000009127 Glutaminase Human genes 0.000 description 1
108010073324 Glutaminase Proteins 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
244000061629 Hygrophila erecta Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
241000337636 Kalama Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102220530046 N-chimaerin_E13S_mutation Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000750004 Nestor meridionalis Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108050008598 Phosphoesterases Proteins 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
101000777312 Rattus norvegicus Choline kinase alpha Proteins 0.000 description 1
101000777311 Rattus norvegicus Choline/ethanolamine kinase Proteins 0.000 description 1
101001047152 Rattus norvegicus UMP-CMP kinase Proteins 0.000 description 1
208000037169 Retrograde Degeneration Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
241000212342 Sium Species 0.000 description 1
208000036982 Spinal cord ischaemia Diseases 0.000 description 1
208000020339 Spinal injury Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
PRSMTOHTFYVJSQ-UHFFFAOYSA-N [Ca].[Pb] Chemical compound [Ca].[Pb] PRSMTOHTFYVJSQ-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000002075 anti-alcohol Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
XITRBUPOXXBIJN-UHFFFAOYSA-N bis(2,2,6,6-tetramethylpiperidin-4-yl) decanedioate Chemical compound C1C(C)(C)NC(C)(C)CC1OC(=O)CCCCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1 XITRBUPOXXBIJN-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000034526 bruise Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
230000009460 calcium influx Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000021617 central nervous system development Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000000330 cholinergic fiber Anatomy 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000003245 coal Substances 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000001947 dentate gyrus Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000001094 effect on targets Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000000928 excitatory amino acid agonist Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
230000009760 functional impairment Effects 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000007387 gliosis Effects 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000000848 glutamatergic effect Effects 0.000 description 1
125000005639 glycero group Chemical group 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
230000002061 histotrophic effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000008676 import Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000010365 information processing Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000005351 kimble Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
230000008449 language Effects 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000028252 learning or memory Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000007787 long-term memory Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000001767 medulla oblongata Anatomy 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000005272 metallurgy Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
239000002052 molecular layer Substances 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
230000003088 neuroexcitatory effect Effects 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
230000007996 neuronal plasticity Effects 0.000 description 1
230000007511 neuronal proliferation Effects 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000004451 qualitative analysis Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000007832 reinnervation Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002186 septum of brain Anatomy 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
230000006886 spatial memory Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
235000013547 stew Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

JP1511596A 1988-10-18 1989-10-16 生体内の神経栄養、細胞保護性アルコール Pending JPH04505003A (ja)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date
US259,964		1981-05-04
US25991988A	1988-10-18	1988-10-18
US25991888A	1988-10-18	1988-10-18
US25996488A	1988-10-18	1988-10-18
US25992888A	1988-10-18	1988-10-18
US259,918		1988-10-18
US259,928		1988-10-18
US259,919		1988-10-18
US26930088A	1988-11-09	1988-11-09
US269,300		1988-11-09

Publications (1)

Publication Number	Publication Date
JPH04505003A true JPH04505003A (ja)	1992-09-03

Family

ID=27540413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1511596A Pending JPH04505003A (ja)	1988-10-18	1989-10-16	生体内の神経栄養、細胞保護性アルコール

Country Status (8)

Country	Link
US (1)	US5135956A (da)
EP (1)	EP0439544B1 (da)
JP (1)	JPH04505003A (da)
AU (1)	AU633526B2 (da)
CA (1)	CA2000940A1 (da)
DE (1)	DE68913756T2 (da)
DK (1)	DK69091A (da)
WO (1)	WO1990004388A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5166317A (en) *	1988-10-31	1992-11-24	Houston Biotechnology Incorporated	Neurotrophic factor
US5070107A (en) *	1989-04-28	1991-12-03	Lidak Pharmaceuticals	Systemic antiviral treatment
US5071879A (en) *	1989-04-28	1991-12-10	Lidak Pharmaceuticals	Systemic antiviral treatment
WO1991005754A2 (fr) *	1989-10-13	1991-05-02	Medafor	Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophiques et cytoprotectrices, et compositions pharmaceutiques les contenant
US5444042A (en) *	1990-12-28	1995-08-22	Cortex Pharmaceuticals	Method of treatment of neurodegeneration with calpain inhibitors
US6174862B1 (en) *	1991-04-22	2001-01-16	Ramot University Authority For Applied Research And Industrial Development, Ltd.	Neurotrophic peptides of activity dependent neurotrophic factor
US5569670A (en) *	1992-06-05	1996-10-29	Asta Medica Aktiengesellschaft	Combination medications containing alpha-lipoic acid and related
WO1994027602A1 (en) *	1993-06-01	1994-12-08	Cortex Pharmaceuticals, Inc.	Use of metabotropic receptor agonists in progressive neurodegenerative deseases
US5952392A (en) *	1996-09-17	1999-09-14	Avanir Pharmaceuticals	Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en)	1996-09-17	2002-08-27	Avanir Pharmaceuticals	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5906976A (en) *	1996-10-22	1999-05-25	Ramot-University Authority For Applied Research And Industrial Development, Ltd.	Method and composition for treating neuronal degeneration
US6962930B1 (en)	1997-06-06	2005-11-08	Lohocla Research Corporation	Compounds, compositions and method suitable for amelioration of withdrawal syndromes and withdrawal-induced brain damage
IT1294227B1 (it) *	1997-08-01	1999-03-24	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
US6506378B1 (en)	1998-12-16	2003-01-14	Arch Development Corporation	Vesicular monoamine transporter gene therapy in Parkinson's disease
US6265147B1 (en)	1999-12-01	2001-07-24	The Board Of Trustees Of The Leland Stanford Junior University	Method of screening for neuroprotective agents
HRP20040421B1 (hr) *	2001-10-16	2013-05-31	Avanir Pharmaceuticals	INHIBICIJA VIRUSA n-DOKOZANOLOM
US7214394B2 (en) *	2002-05-31	2007-05-08	Archer-Daniels-Midland Company	Policosanol compositions, extraction from novel sources, and uses thereof
US20050074443A1 (en) *	2003-10-03	2005-04-07	Treadwell Benjamin V.	Methods of attenuating autoimmune disease and compositions useful therefor
US8202541B2 (en) *	2006-02-07	2012-06-19	U.S. Nutraceuticals, LLC	Dietary supplement composition for blood lipid health
JP5173018B2 (ja) *	2008-04-03	2013-03-27	エフ．ホフマン−ラロシュアーゲー	神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
WO2013082299A1 (en)	2011-11-29	2013-06-06	Als Therapy Development Institute	Targeting of t-lymphocytes to treat amyotrophic lateral sclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3031376A (en) *	1956-10-11	1962-04-24	Levin	Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US4186212A (en) *	1978-03-09	1980-01-29	Howell F Maurice	Animal feed containing high molecular weight aliphatic alcohols
US5055613A (en) *	1988-02-18	1991-10-08	G. D. Searle & Co.	Metabolites of pentanedioic acid derivatives
US4874794A (en) *	1989-04-28	1989-10-17	Lidak Biopharmaceuticals	Inflammatory disease treatment

1989
- 1989-10-13 US US07/420,904 patent/US5135956A/en not_active Expired - Fee Related
- 1989-10-16 JP JP1511596A patent/JPH04505003A/ja active Pending
- 1989-10-16 WO PCT/US1989/004630 patent/WO1990004388A1/en not_active Ceased
- 1989-10-16 AU AU45108/89A patent/AU633526B2/en not_active Ceased
- 1989-10-16 EP EP89912595A patent/EP0439544B1/en not_active Expired - Lifetime
- 1989-10-16 DE DE68913756T patent/DE68913756T2/de not_active Expired - Fee Related
- 1989-10-18 CA CA002000940A patent/CA2000940A1/en not_active Abandoned
1991
- 1991-04-17 DK DK069091A patent/DK69091A/da unknown

Also Published As

Publication number	Publication date
DK69091A (da)	1991-06-14
EP0439544B1 (en)	1994-03-09
WO1990004388A1 (en)	1990-05-03
DE68913756T2 (de)	1994-08-11
US5135956A (en)	1992-08-04
DK69091D0 (da)	1991-04-17
AU4510889A (en)	1990-05-14
AU633526B2 (en)	1993-02-04
EP0439544A1 (en)	1991-08-07
DE68913756D1 (de)	1994-04-14
CA2000940A1 (en)	1990-04-18

Publication	Publication Date	Title
JPH04505003A (ja)	1992-09-03	生体内の神経栄養、細胞保護性アルコール
Angelov et al.	1996	Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve
US5521215A (en)	1996-05-28	NMDA-blocking pharmaceuticals
US11207333B2 (en)	2021-12-28	Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
RU2217140C2 (ru)	2003-11-27	Применение замещенных аминометил-хроманов для предотвращения дегенерации и для ускорения регенерации нервных клеток
US12084471B2 (en)	2024-09-10	Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same
PT973872E (pt)	2002-01-30	Utilizacao de factor de crescimento de nervos para a armazenagem cultura ou tratamento da cornea
CN116801866B (zh)	2025-09-02	α-细辛脑在制备预防或治疗出血性脑卒中药物中的应用
JP6835738B2 (ja)	2021-02-24	軸索障害の処置用のパルテノライドおよびその誘導体
DE69826653T2 (de)	2006-03-09	Bpc peptid salze mit organ-schützender aktivität, deren herstellung und therapeutische verwendung
KR100794204B1 (ko)	2008-01-14	신경 친화성 타크로리무스 유사체
Fondacaro et al.	1990	Cecectomized rat: a model of experimental secretory diarrhea in conscious animals
DE69426316T2 (de)	2001-05-03	Verwendung von Beta-Naphthochinonderivaten zur Beschleunigung der Proliferation der Endothelzellen und Inhibierung der NO-Synthasen
RU2766083C1 (ru)	2022-02-07	Биологически активная субстанция в виде биорегуляторной композиции, обладающая поддерживающим и восстановительным действием на ткани и органы, и фармакологическая композиция
DE69519219T2 (de)	2001-02-22	Verwendung von (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamid zur Behandlung von Keratopathie
JPWO2019077810A1 (ja)	2020-11-05	ペリオスチン及びｐｋｍ２の分泌促進剤
Lescaudron et al.	1990	Functional recovery following transplants of embryonic brain tissue in rats with lesions of visual, frontal and motor cortex: problems and prospects for future research
WO1988006037A1 (fr)	1988-08-25	Utilisation de sulfate de dextrane pour produire des medicaments therapeutiques et prophylactiques contre les vaso-constrictions et les vaso-occlusions
RU2825666C2 (ru)	2024-08-28	Терапевтическое средство для лечения заболевания нервной системы
AU2299499A (en)	1999-08-23	Remedies for neurological disorders
Wen et al.	2018	Recovery of respiratory function and autonomic diaphragm movement following unilateral recurrent laryngeal nerve to phrenic nerve anastomosis in rabbits
EP3949960A1 (en)	2022-02-09	Compounds (in particular salotenolide) in the treatment of axonal damage
CN115475162A (zh)	2022-12-16	4-异丁基-2-吡咯烷酮在制备镇痛药物中的应用、一种镇痛药物
Nieto-Sampedro	2004	Neural plasticity and central nervous system lesion repair
Pyapali et al.	1994	Fetal transplants in rat hippocampus following kainic acid lesions: influence of post-lesion delay on graft survival and integration